Inventiva S.A. (IVA) Stock Forecast & Price Target

Inventiva is supported by lanifibranor’s differentiated pan-PPAR profile, which in Phase 2b delivered a 26% placebo-adjusted composite response and 18% fibrosis improvement at 24 weeks, with management guiding that 18% fibrosis improvement in Phase 3 would be excellent. The 72-week NATiV3 design, favorable baseline mix with more F3 and diabetic patients, and blinded interim data showing overlapping hepatic, lipid, glycemic, and fibrosis markers with Phase 2 all strengthen conviction that efficacy can deepen while placebo response stays manageable. Financially, the company reported €166.1M of cash plus €67.8M in short-term deposits as of June 30, 2026, supporting a runway into 2Q2027 and potentially into 1Q2028 with structured financing, while a large MASH market and partnerships in greater China, Japan, and South Korea provide meaningful longer-term upside.

Inventiva is challenged by a riskier safety profile for lanifibranor, including edema, weight gain of about 3-4% on average and roughly 33% of patients with >5% weight gain, plus concerns about liver toxicity, cardiac events and fracture risk from PPARγ modulation. Its efficacy case also looks less compelling because older MASH endpoints, modest fibrosis data and the possibility of stronger competitors like Rezdiffra and future FGF21 agonists could limit differentiation and adherence. On top of that, composition-of-matter protection expires in 2026, it is still expected to need financing for clinical trials and commercialization, and broader patent reliance into 2041 remains uncertain.